FDA Overhauls HRT Warnings, Citing Evolving Science on Menopause

WHITE OAK, MD – February 12, 2026 – In a decision that reshapes the landscape of menopause care, the U.S. Food and Drug Administration today approved the removal of its most severe safety warnings from a class of widely used menopausal hormone therapy products. The agency announced that risk statements related to cardiovascular disease, breast cancer, and probable dementia will be eliminated from the “boxed warning” on six initial products, with more expected to follow.

The move marks a pivotal reversal of a two-decade-old stance that cast a long shadow of fear over hormone replacement therapy (HRT), causing millions of women and their doctors to shun the treatments. Today’s action is based on a comprehensive review of scientific evidence that has largely dismantled the conclusions of a landmark 2002 study.

“This decision reflects our commitment to follow the science wherever it leads and to correct course when the evidence demands it,” Health and Human Services Secretary Robert F. Kennedy, Jr. said in a statement. “By removing these boxed warnings, we ensure that women receive accurate information about hormone therapy—free from exaggeration or fear.”

A Two-Decade Shadow Lifts

The story of HRT’s fall from grace began in 2002 with the early termination of a major study from the Women’s Health Initiative (WHI). Its initial findings linked the most common form of combined hormone therapy to an increased risk of heart disease, stroke, and breast cancer. In response, the FDA mandated a “black box” warning—its strongest caution—for HRT products in 2003, and prescriptions plummeted.

However, in the years since, a wave of scientific re-evaluation has fundamentally challenged those initial conclusions. Researchers and medical societies have pointed out critical flaws in the original interpretation, noting that the average age of participants in the WHI trial was 63, with many being more than a decade past menopause. This demographic is now understood to face different risks than women who begin therapy closer to the onset of menopause.

Today, the scientific consensus, endorsed by organizations like the North American Menopause Society (NAMS), is that for most healthy women who start HRT before age 60 or within 10 years of their last period, the benefits of treatment often outweigh the risks. The FDA’s decision formally aligns its regulatory guidance with this modern understanding.

“With today’s action, we are delivering on our promise to make sure women have accurate, scientifically grounded information about the potentially life-changing benefits of HRT,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Women face symptoms of menopause that can last for years, and our efforts will help these women make well-informed medical decisions.”

Following the Science: What the New Evidence Shows

The FDA’s removal of the boxed warnings is not a declaration that HRT is risk-free, but rather a crucial recalibration of where those risks lie. The agency’s review, initiated in November 2025, confirmed what many specialists have argued for years: timing is everything.

• Cardiovascular Disease and Mortality: Contrary to the initial WHI panic, subsequent analyses and randomized studies show that women who begin HRT in early menopause (before age 60) do not have an increased risk of coronary heart disease. In fact, some data suggest a reduction in all-cause mortality for this group. The NAMS 2022 position statement notes that some forms of therapy, particularly those delivered through the skin (transdermal), may carry even lower risks of stroke and blood clots.

• Breast Cancer: The fear of breast cancer has been one of the biggest deterrents to HRT use. However, updated evidence provides a more nuanced picture. Estrogen-only therapy, used by women who have had a hysterectomy, has been associated with a reduced risk of breast cancer. For combined estrogen-progestogen therapy, studies show the risk does not increase significantly with short-term use and remains small over the long term.

• Dementia: The warning about “probable dementia” also stemmed from the WHI study of older women. More recent research has failed to find a link between HRT and dementia when started in early menopause. Some studies have even suggested a potential protective effect, though experts agree more research is needed to clarify this relationship.

Impact on Patients and Prescribers

The practical implications of this regulatory shift are immense. Menopause can bring on debilitating symptoms, including severe hot flashes, night sweats, vaginal atrophy, and an increased risk of osteoporosis. Yet, due to lingering fears, only a fraction of women who could benefit from treatment are receiving it. In 2020, an estimated 41 million U.S. women were between the ages of 45 and 64, but only about 2 million received an HRT prescription.

The removal of the boxed warnings is expected to empower both patients and healthcare providers to engage in more open and informed conversations. It removes a significant psychological and perceived medico-legal barrier for primary care physicians who may have been hesitant to prescribe the therapies.

This change emphasizes a move toward personalized medicine. The decision of whether to use HRT will still depend on an individual woman’s health profile, symptom severity, and personal preferences. Certain warnings will remain; for example, systemic estrogen-only therapy will still carry a warning about endometrial cancer, underscoring the need for women with a uterus to also take a progestogen to protect the uterine lining.

A New Chapter for Menopause Treatment

The FDA’s action is poised to trigger a significant shift in the pharmaceutical market for menopause treatments. In response to the agency's review, 29 drug companies submitted proposals for labeling changes. The first six products to receive approval represent the full range of available therapies and include Bijuva (a systemic combination therapy), Divigel (a systemic estrogen-alone therapy), and Estring (a topical vaginal estrogen therapy).

This broad industry participation signals the start of a potential renaissance in menopause management. With the most alarming warnings removed, pharmaceutical companies may invest more in education and outreach, and a market that has been suppressed for two decades could see substantial growth.

More importantly, the decision represents a major public health victory for women's health advocates who have long argued that the demonization of HRT has caused unnecessary suffering. By aligning its regulations with the current body of evidence, the FDA is helping to ensure that a woman’s quality of life is a central part of the conversation around menopause, moving beyond fear and toward informed, individualized choice.